Sugi Predict

Sugi Predict / Compounds / SCHEMBL1623666

SCHEMBL1623666

SCHEMBL1623666

CC(C)(C)CC(O)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ OR51E2 Q9H255 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ TET2 Q6N021 6/20 0.40
▸ KDM4A O75164 2/20 0.40
▸ KDM4C Q9H3R0 2/20 0.40
▸ KDM2A Q9Y2K7 2/20 0.40
▸ TET3 O43151 2/20 0.40
▸ GPR84 Q9NQS5 3/20 0.39
▸ FFAR1 O14842 1/20 0.39
▸ TP53 P04637 1/20 0.38
▸ TET1 Q8NFU7 1/20 0.37
▸ PGK1 P00558 1/20 0.34
▸ PGK2 P07205 1/20 0.34
▸ GRN P28799 1/20 0.34
▸ SORT1 Q99523 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ PTGS1 P23219 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1953735 1.00 OR51E2 (0.46) OR51E2SMN1; SMN2TET2KDM4AKDM4C
SCHEMBL1621576 1.00 OR51E2 (0.46) OR51E2SMN1; SMN2TET2KDM4AKDM4C
SCHEMBL28657075 0.97 OR51E2 (0.43) OR51E2SMN1; SMN2TET2KDM4AKDM4C
SCHEMBL29450633 0.97 OR51E2 (0.43) OR51E2SMN1; SMN2TET2KDM4AKDM4C
SCHEMBL30138110 0.97 OR51E2 (0.43) OR51E2SMN1; SMN2TET2KDM4AKDM4C
SCHEMBL19436359 0.97 OR51E2 (0.43) OR51E2SMN1; SMN2TET2KDM4AKDM4C
Benzene SCHEMBL28220562 0.95 OR51E2 (0.42) OR51E2SMN1; SMN2TET2KDM4AKDM4C
SCHEMBL1068580 0.85 OR51E2 (0.39) OR51E2SMN1; SMN2TET2KDM4AKDM4C
SCHEMBL23777976 0.81 OR51E2 (0.43) OR51E2SMN1; SMN2TET2KDM4AKDM4C
SCHEMBL8971302 0.79 OR51E2 (0.37) OR51E2SMN1; SMN2TET2KDM4AKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111205397-B Ionic liquid grafted cellulose nanocrystal and preparation method thereof 青岛科技大学 2022-08-23 — — CN claimed
CN-111205397-A Ionic liquid grafted cellulose nanocrystal and preparation method thereof 青岛科技大学 2020-05-29 — — CN claimed
WO-2015063543-A1 HYDRIDOPALLADIUM(II) HALIDES AS PREFORMED CATALYSTS FOR SUZUKI-MIYAURA CROSS-COUPLING REACTIONS LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) 2015-05-07 — — WO claimed
US-20070179045-A1 Mixed catalytic composition PMC VLISSINGEN NETHERLANDS, B.V. (NL) 2007-08-02 — — US claimed
EP-1326993-B1 PRODUCTION OF ALPHA-HYDROXY-CARBOXYLIC ACIDS USING A COUPLED ENZYME SYSTEM EXCELSYN MOLECULAR DEV LTD (GB) 2007-05-23 — — EP claimed
CN-1358178-A Pharmaceutical compounds NICOX SA (FR) 2002-07-10 — — CN claimed
EP-4444708-B1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER (US) 2025-07-30 — — EP disclosed
US-20250179248-A1 MECHANOCHEMICAL-REACTION ADDITIVE, MECHANOCHEMICAL METHOD, LIGAND COMPOUND, AND COMPLEX NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) 2025-06-05 — — US disclosed
US-20250129048-A1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER INC. (US) 2025-04-24 — — US disclosed
EP-4488249-A1 MECHANOCHEMICAL-REACTION ADDITIVE, MECHANOCHEMICAL METHOD, LIGAND COMPOUND, AND COMPLEX National University Corporation Hokkaido University (JP) 2025-01-08 — — EP disclosed
US-20240397944-A1 METHODS FOR BIOFILM DISRUPTION Lixa Limited (AU) 2024-12-05 — — US disclosed
EP-4444708-A1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF Pfizer Inc. (US) 2024-10-16 — — EP disclosed
WO-2023167321-A1 MECHANOCHEMICAL REACTION ADDITIVE, MECHANOCHEMICAL METHOD, LIGAND COMPOUND, AND COMPLEX 国立大学法人北海道大学 2023-09-07 — — WO disclosed
US-20030013700-A1 Thrombin inhibitors MERCK SHARP & DOHME CORP. 2003-01-16 — — US disclosed
CN-1358178-A Pharmaceutical compounds NICOX SA (FR) 2002-07-10 — — CN disclosed
US-20020065261-A1 Anticarcinogenic agent with low toxicity UNIVERSITY OF HAWAII 2002-05-30 — — US disclosed
WO-2002033110-A2 PRODUCTION OF α-HYDROXY-CARBOXYLIC ACIDS USING A COUPLED ENZYME SYSTEM PCBU SERVICES, INC. (US) 2002-04-25 — — WO disclosed
US-6355643-B1 ENZYME INHIBITORS, RAS GENES AND PROTEINS MERCK & CO., INC. 2002-03-12 — — US disclosed
EP-1158983-A1 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE Merck & Co., Inc. (US) 2001-12-05 — — EP disclosed
WO-2000051612-A1 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 2000-09-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013700-A1 Thrombin inhibitors TFPI, PLAT, TFPI2 OR51E2 1692/4885SMN1; SMN2 3710/4885TET2 532/4885
US-20240397944-A1 METHODS FOR BIOFILM DISRUPTION FGB, MMP8, HAO2 OR51E2 3431/4885SMN1; SMN2 4874/4885TET2 464/4885
US-20020065261-A1 Anticarcinogenic agent with low toxicity HCCS, TP53, GSTA1 OR51E2 4298/4885SMN1; SMN2 3725/4885TET2 2795/4885
US-20250129048-A1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF MC4R, MC3R, MC2R OR51E2 2256/4885SMN1; SMN2 1912/4885TET2 2099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.